Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Jun 3.

Published in final edited form as: Prostaglandins Other Lipid Mediat. 2010 Dec 15;94(0):44–52. doi: 10.1016/j.prostaglandins.2010.12.003

Table 1.

Sphingolipid profile in LPS-treated Raw264.7 cells

Sphingolipids (pmole/mg)	Control	LPS	LPS + Despiramine (20 μM)
C14:0 Cer	10.1 ± 0.1	11.0 ± 0.3	11.5 ± 0.2
C16:0 Cer	77.3 ± 3.8	212.7 ± 19.4^*	292.5 ± 22.4 ^§
C18:0 Cer	0.5 ± 0.1	10.7 ± 1.5^*	17.6 ± 1.7^*^§
C18:1 Cer	15.4 ± 0.1	15.6 ± 0.1	14.9 ± 0.1
C24:0 Cer	231.6 ± 15.8	423.3 ± 32.6^*	351.0 ± 41.7^*^§
C24:1 Cer	77.9 ± 5.5	90.3 ± 10.8	98.7 ± 8.0^§
SO	76.5 ± 2.0	87.8 ± 1.1^*	67.2 ± 0.1^§
SM 16:0	25167 ± 1572	48973 ± 5033^*	33131 ± 3066^§
SM 18:0	1401 ± 156	2713 ± 380^*	2299 ± 238^*
SM18:1	80.2 ± 5.0	154.4 ± 30.3^*	163.5 ± 27.5

pmole/mg protein, Cer, ceramide; SO, sphingosine; SM, sphingomyelin. n=3.

^*

p<0.05 vs. Control.

^§

p<0.05 vs. LPS.